Physician profile
John C Holder
NPI 1093949463
$9,327.24
in general payments reported to CMS, 2019-2025
37 companies · $846 in 2025
The $846 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $404 · 2020: $893 · 2021: $800 · 2022: $2,765 · 2023: $1,347 · 2024: $2,272 · 2025: $846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,566 · Travel and Lodging: $899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,566.10 |
| Travel and Lodging | $899.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,768.17 | 2019-2025 | Wavewriter Alpha Prime 16, Superion Indirect Decompression System |
| Medtronic, INC. | $2,063.78 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Kyphon Express II Kyphopak Tray |
| Abbvie INC. | $864.59 | 2021-2025 | |
| Abbott Laboratories | $543.17 | 2019-2025 | Eterna, Proclaim |
| Pfizer INC. | $323.34 | 2019-2025 | |
| Amgen INC. | $322.06 | 2019-2022 | |
| Medtronic USA, INC. | $317.33 | 2019-2020 | |
| Allergan, INC. | $173.14 | 2020-2022 | |
| Nevro Corp. | $147.99 | 2024 | Senza |
| Collegium Pharmaceutical, INC. | $146.38 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $119.88 | 2020-2021 | |
| Virtus Pharmaceuticals LLC | $117.41 | 2023-2025 | Levorphanol Tartrate |
| Forte Bio-Pharma LLC | $116.96 | 2020-2023 | Prolate, Nalocet |
| Globus Medical, INC. | $109.25 | 2025 | Senza |
| Redhill Biopharma INC. | $108.53 | 2020-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $101.11 | 2020-2022 | |
| Si-Bone, INC. | $95.05 | 2022-2023 | |
| Lilly USA, LLC | $86.15 | 2020-2023 | Reyvow, Emgality |
| Lundbeck LLC | $74.38 | 2021-2023 | Vyepti |
| Merz Pharmaceuticals, LLC | $74.11 | 2022-2025 | Xeomin |
| Mdd US Operations, LLC | $70.34 | 2022 | |
| Painteq LLC | $65.72 | 2024 | Painteq |
| Biohaven Pharmaceutical Holding Company Ltd. | $64.50 | 2022 | |
| Horizon Therapeutics Plc | $61.77 | 2020 | |
| Daiichi Sankyo INC. | $53.77 | 2019 | |
| Arbor Pharmaceuticals, INC. | $50.77 | 2020-2022 | |
| Almatica Pharma LLC | $43.30 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $42.95 | 2022-2023 | Seglentis |
| Ibsa Pharma INC. | $37.29 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $26.18 | 2019 | |
| Kaleo, INC. | $24.88 | 2019 | |
| Stryker Corporation | $24.36 | 2025 | Optablate |
| Takeda Pharmaceuticals U.S.A., INC. | $23.96 | 2019 | |
| Bioventus LLC | $22.41 | 2025 | Gelsyn-3 |
| Tersera Therapeutics LLC | $15.55 | 2020 | |
| Novo Nordisk INC | $15.05 | 2023 | Wegovy |
| Pernix Therapeutics Holdings, INC. | $11.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Holder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.